Macromolecular Bioscience,
Journal Year:
2023,
Volume and Issue:
24(3)
Published: Aug. 13, 2023
Abstract
Cancer
development
and
progression
of
cancer
are
closely
associated
with
the
activation
oncogenes
loss
tumor
suppressor
genes.
Nucleic
acid
drugs
(e.g.,
siRNA,
mRNA,
DNA)
widely
used
for
therapy
due
to
their
specific
ability
regulate
expression
any
cancer‐associated
However,
nucleic
negatively
charged
biomacromolecules
that
susceptible
serum
nucleases
cannot
cross
cell
membrane.
Therefore,
delivery
tools
required
facilitate
intracellular
drugs.
In
past
few
decades,
a
variety
nanoparticles
(NPs)
designed
developed
therapy.
particular,
polymeric
NPs
in
response
abnormal
redox
status
cells
have
garnered
much
more
attention
as
potential
redox‐triggered
nanostructure
dissociation
rapid
release
this
review,
important
genes
or
signaling
pathways
regulating
briefly
introduced
recent
redox‐responsive
is
systemically
summarized.
The
future
NPs‐mediated
challenges
clinical
translation
also
discussed.
Frontiers in Bioengineering and Biotechnology,
Journal Year:
2023,
Volume and Issue:
11
Published: Feb. 2, 2023
Applying
reactive
polymer
materials
sensitive
to
biological
stimuli
has
recently
attracted
extensive
research
interest.
The
special
physiological
effects
of
oxygen
species
(ROS)
on
tumors
or
inflammation
and
the
application
ROS-responsive
polymers
as
drug-delivery
systems
in
organisms
have
much
attention.
ROS
is
a
vital
disease
signal
molecule,
unique
accumulation
pathological
sites
may
enable
deliver
payload
(such
drugs,
prodrugs,
gene
therapy
fragments)
targeted
fashion.
In
this
paper,
progress
their
recent
years
were
summarized
analyzed.
was
reviewed
from
perspective
nanoparticle
drug
delivery
systems,
multi-responsive
hydrogels.
It
expected
that
our
work
will
help
understand
future
development
trends
field.
Journal of Translational Medicine,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: Jan. 5, 2024
Abstract
Acute
lung
injury
(ALI)
is
a
complex
disease
with
numerous
causes.
This
review
begins
discussion
of
development
from
direct
or
indirect
pulmonary
insults,
as
well
varied
pathogenesis.
The
heterogeneous
nature
ALI
then
elaborated
upon,
including
its
epidemiology,
clinical
manifestations,
potential
biomarkers,
and
genetic
contributions.
Although
no
medication
currently
approved
for
this
devastating
illness,
supportive
care
pharmacological
intervention
treatment
are
summarized,
followed
by
an
assessment
the
pathophysiological
gap
between
human
animal
models.
Lastly,
current
research
progress
on
advanced
nanomedicines
therapeutics
in
preclinical
settings
reviewed,
demonstrating
new
opportunities
towards
developing
effective
ALI.
Cell Biology International,
Journal Year:
2022,
Volume and Issue:
46(9), P. 1320 - 1344
Published: July 13, 2022
Abstract
Immune‐mediated
diseases
(IMDs)
are
chronic
conditions
that
have
an
immune‐mediated
etiology.
Clinically,
these
appear
to
be
unrelated,
but
pathogenic
pathways
been
shown
connect
them.
While
inflammation
is
a
common
occurrence
in
the
body,
it
may
either
stimulate
favorable
immune
response
protect
against
harmful
signals
or
cause
illness
by
damaging
cells
and
tissues.
Nanomedicine
has
tremendous
promise
for
regulating
treating
IMIDs.
Various
nanoparticles
coated
with
nanotherapeutics
recently
fabricated
effective
targeted
delivery
inflammatory
RNA
interference
(RNAi)
offers
genetic
approach,
particularly
if
traditional
treatments
ineffective
IMDs.
In
cells,
several
signaling
can
suppressed
using
RNAi,
which
blocks
expression
of
particular
messenger
RNAs.
Using
this
molecular
undesirable
effects
anti‐inflammatory
medications
reduced.
Still,
there
many
problems
short‐interfering
RNAs
(siRNAs)
treat
IMDs,
including
poor
localization
siRNAs
target
tissues,
unstable
gene
expression,
quick
removal
from
blood.
Nanotherapeutics
widely
used
designing
siRNA‐based
carriers
because
restricted
therapy
options
review,
we
discussed
recent
trends
fabrication
siRNA
nanodelivery
systems,
lipid‐based
nanocarriers,
liposomes,
cationic
lipids,
stable
nucleic
acid‐lipid
particles,
polymeric‐based
polyethylenimine
(PEI)‐based
nanosystems,
chitosan‐based
nanoformulations,
inorganic
material‐based
hybrid‐based
systems.
We
also
introduced
novel
nanocarriers
control
IMIDs,
such
as
pulmonary
inflammation,
psoriasis,
bowel
disease,
ulcerative
colitis,
rheumatoid
arthritis,
etc.
This
study
will
pave
way
new
avenues
research
into
diagnosis
treatment
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(18), P. 17845 - 17857
Published: Sept. 15, 2023
Brain
inflammation
is
regarded
as
one
of
the
leading
causes
that
aggravates
secondary
brain
injury
and
hinders
prognosis
ischemic
stroke.
After
stroke,
high
quantities
peripheral
neutrophils
are
recruited
to
lesions
release
neutrophil
extracellular
traps
(NETs),
aggravation
blood-brain
barrier
(BBB)
damage,
activation
microglia,
ultimate
neuronal
death.
Herein,
a
smart
multifunctional
delivery
system
has
been
developed
regulate
immune
disorders
in
brain.
Briefly,
Cl-amidine,
an
inhibitor
peptidylarginine
deiminase
4
(PAD4),
encapsulated
into
self-assembled
liposomal
nanocarriers
(C-Lipo/CA)
modified
by
reactive
oxygen
species
(ROS)-responsive
polymers
fibrin-binding
peptide
achieve
targeting
stimuli-responsive
drug.
In
mouse
model
cerebral
artery
occlusion/reperfusion
(MCAO),
C-Lipo/CA
can
suppress
NETs
process
(NETosis)
further
inhibit
cyclic
guanosine
monophosphate-adenosine
monophosphate
synthase-stimulator
interferon
genes
(cGAS-STING)
pathway
addition,
MCAO
mice
treated
with
significantly
mitigated
reperfusion
injury,
reduction
area
infarction
12.1%,
compared
saline
group
about
46.7%.
These
results
demonstrated
C-Lipo/CA,
which
integrated
microglia
regulation,
BBB
protection,
neuron
survival,
exerts
potential
therapy
strategy
maximize
ameliorating
mortality
ACS Applied Materials & Interfaces,
Journal Year:
2023,
Volume and Issue:
15(22), P. 26298 - 26315
Published: May 26, 2023
Intestinal
immune
dysfunction
and
gut
microbiota
dysbiosis
are
critically
causative
factors
in
the
pathogenesis
of
ulcerative
colitis
(UC);
however,
current
first-line
drugs
for
UC
treatment
clinics
often
remain
great
challenges
due
to
their
nontargeting
therapeutic
efficacy
severe
side
effects.
In
study,
colon-targeting
nanoparticles
based
on
Angelica
sinensis
polysaccharide
with
pH-
redox-responsiveness
were
fabricated
specifically
release
naturally
active
compound
ginsenoside
Rh2
colonic
inflammatory
site,
which
greatly
alleviated
symptoms
improved
microbial
homeostasis.
These
dual
responsive
Rh2-loaded
(Rh2/LA-UASP
NPs)
a
particle
size
117.00
±
4.80
nm
prepared
using
polymer
LA-UASP
obtained
by
grafting
A.
urocanic
acid
α-lipoic
(α-LA).
As
expected,
these
Rh2/LA-UASP
NPs
achieved
redox-responsive
drug
at
pH
5.5
10
mM
GSH.
The
stability,
biocompatibility,
vivo
safety
experiments
exhibited
had
excellent
ability
significant
accumulation
colon.
Meanwhile,
could
escape
from
lysosomes
be
efficiently
internalized
into
intestinal
mucosal
cells,
thereby
effectively
inhibiting
proinflammatory
cytokines.
animal
indicated
that
significantly
integrity
mucosa
increased
colon
length
compared
mice.
Additionally,
weight
loss,
histological
damage,
inflammation
level
ameliorated.
homeostasis
flora
short-chain
fatty
acids
(SCFAs)
after
being
treated
Our
study
proved
pH-and
promising
candidates
treatment.
Advanced Functional Materials,
Journal Year:
2023,
Volume and Issue:
33(30)
Published: April 26, 2023
Abstract
Vascular
restenosis
after
balloon
dilation
is
largely
caused
by
the
over‐proliferation
of
smooth
muscle
cells,
which
triggered
and
exacerbated
local
excessive
inflammation
oxidative
stress.
The
inflammatory
stress
cause
tissue/cell
damage,
hamper
endothelial
functions,
worsen
intimal
hyperplasia
restenosis.
A
high
level
reactive
oxygen
species
(ROS)
overproduction
regarded
as
main
culprit.
Therefore,
efficiently
inhibiting
ROS
over‐production
or
weightily
depleting
them
great
significance.
Herein,
a
“ROS‐responsive/scavenging
prodrug”
introduced
into
coating
for
treatment
vascular
reversible
phenylboronic
ester‐bearing
caffeic
acid
(CA)
macromolecular
prodrug
(PBC)
designed
controlled
on‐demand
dual‐drug
release
level;
released
CA
4‐hydroxybenzyl
alcohol
exhibit
efficient
antioxidant
anti‐inflammatory
effects
scavenging
ROS,
thereby
regulating
microenvironment
protecting
endothelium
functions.
To
accelerate
regeneration,
pro‐endothelial
microRNA‐126
further
introduced.
ROS‐responsive/scavenging
prodrug/miRNA
prevents
hyperplasia,
alleviates
inflammation,
improves
healing
in
rat
abdominal
aorta
model,
may
provide
applicative
perspectives
next‐generation
drug‐coated
balloons
other
cardiovascular
diseases
treatment.
